EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Global Probiotic Markets Meet Synthetic Biology: Translational Challenges and Escherichia coli Nissle 1917 as a Model Chassis

Jinjin Chen, C Perry Chou iD, Yilan Liu iD

Microorganisms · 11.06.2026 · 14 (6) · 1306

DOI: 10.3390/microorganisms14061306 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Microorganisms, online erschienen am 11.06.2026. Verfasst von Jinjin Chen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical Engineering, University of Waterloo, 200 University Avenue West, Waterloo, ON N2L 3G1, Canada. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Sciences and Engineering Research Council of Canada, University of Waterloo, the Natural Sciences and Engineering Research Council of Canada (NSERC) Discovery Grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The global probiotic market is expanding rapidly, driven by growing demand for accessible strategies to support gut health, preventive care, and microbiome-based interventions. However, this commercial growth contrasts with the limited number of clinically validated, mechanism-driven products, highlighting a persistent gap between market expansion, scientific evidence, and therapeutic translation. Most current probiotics remain dominated by conventional genera, including Lactobacillus, Bifidobacterium, Bacillus, Saccharomyces, and Streptococcus, whereas live biotherapeutic products (LBPs) remain scarce. Synthetic biology is beginning to address this gap by transforming probiotics from empirically selected strains into programmable microbial platforms that sense disease-associated signals and produce defined therapeutic outputs. Escherichia coli Nissle 1917 (EcN) offers a valuable model chassis for engineered probiotics because of its long history of human use, safety record, genetic tractability, transient gut colonization, and scalable cultivation. As a rare Gram-negative probiotic, EcN naturally produces outer membrane vesicles that support host interaction, immunomodulation, and therapeutic cargo delivery. This review links probiotic market expansion with live biotherapeutic development and uses EcN to discuss emerging engineering strategies, therapeutic opportunities, and remaining translational barriers.

Schlagwörter

Stichwörter der Autor:innen

EcNengineering strategieslive biotherapeutic productsprobiotic marketsynthetic biology

Autor:innen und Institutionen

  • Department of Chemical Engineering, University of Waterloo, 200 University Avenue West, Waterloo, ON N2L 3G1, Canada.

ORCID-Profile: C Perry Chou, Yilan Liu

Förderung

  • Natural Sciences and Engineering Research Council of Canada
  • University of Waterloo
  • the Natural Sciences and Engineering Research Council of Canada (NSERC) Discovery Grant
  • University of Waterloo Velocity Up Start Grant

Zitieren

APA

Chen, J., Chou, C. P., & Liu, Y. (2026). Global Probiotic Markets Meet Synthetic Biology: Translational Challenges and Escherichia coli Nissle 1917 as a Model Chassis. Microorganisms, 14(6), 1306. https://doi.org/10.3390/microorganisms14061306

Vancouver

Chen J, Chou CP, Liu Y. Global Probiotic Markets Meet Synthetic Biology: Translational Challenges and Escherichia coli Nissle 1917 as a Model Chassis. Microorganisms. 2026;14(6):1306. doi:10.3390/microorganisms14061306

BibTeX
@article{Chen2026,
  author = {Chen, Jinjin and Chou, C Perry and Liu, Yilan},
  title = {Global Probiotic Markets Meet Synthetic Biology: Translational Challenges and Escherichia coli Nissle 1917 as a Model Chassis},
  journal = {Microorganisms},
  year = {2026},
  volume = {14},
  number = {6},
  pages = {1306},
  doi = {10.3390/microorganisms14061306}
}
Kostenlos starten →